SCHEDULE: FMR LLC Discloses 15% Stake in Apogee Therapeutics
Beneficial Ownership Disclosure
FMR LLC and Abigail P. Johnson have disclosed a 15.0% beneficial ownership stake in Apogee Therapeutics Inc., totaling 6,907,100 common shares.
Summary
- FMR LLC and Abigail P. Johnson jointly reported beneficial ownership of 6,907,100 common shares of Apogee Therapeutics Inc.
- This represents 15.0% of the total outstanding common stock of Apogee Therapeutics Inc.
- The filing is an Amendment No. 3 to a Schedule 13G, indicating a change in previously reported ownership.
- FMR LLC holds sole voting power over 6,907,032 shares and sole dispositive power over 6,907,100 shares.
- Abigail P. Johnson holds sole dispositive power over 6,907,100 shares, with no sole or shared voting power.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 8
Explanation: The disclosure of a significant 15% stake by a major institutional investor like FMR LLC is generally viewed very positively, indicating strong confidence and a long-term investment horizon. This type of filing typically signals a vote of confidence in the company's prospects.
Positives
- Significant institutional investment from FMR LLC, a major asset manager, signals confidence in Apogee Therapeutics Inc.
- The substantial 15.0% stake indicates a strong conviction by a prominent investor.
- The filing states the shares are held in the ordinary course of business, not for control, suggesting a passive investment focus.
Future Outlook
Not applicable. This filing is a disclosure of current beneficial ownership and does not contain forward-looking statements or guidance from the issuer.
Industry Context
This filing indicates a significant investment by a major asset management firm, FMR LLC, in Apogee Therapeutics Inc. While the filing itself does not provide industry-specific context, such a substantial stake from a prominent institutional investor can be viewed as a positive signal within the biotechnology or pharmaceutical sector, suggesting investor confidence in the company's long-term prospects or strategic direction.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Ownership Structure Disclosure | The filing details the beneficial ownership structure of FMR LLC, noting that members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares (49% voting power) and have a voting agreement, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940. | NA | Provides transparency into the ultimate control structure of the reporting entity (FMR LLC) rather than the issuer (Apogee Therapeutics Inc.). This clarifies the reporting entity's internal governance and compliance with SEC regulations regarding beneficial ownership. |
Stakeholder Impact
- Shareholders: Increased confidence due to a large institutional investor's stake, potentially leading to positive market perception and stability.
- Management: May feel validated by the significant institutional investment, potentially influencing strategic decisions to align with long-term investor interests.
- Employees: Indirect positive impact from increased investor confidence, potentially leading to greater stability and growth opportunities.
Key Dates
| Date | Description |
|---|---|
| 2023-05-23 | Effective date of Power of Attorney for Richard Bourgelas on behalf of FMR LLC and Abigail P. Johnson. |
| 2023-08-08 | Date of previous Schedule 13G filing by FMR LLC, referenced for Power of Attorney accession number. |
| 2025-06-30 | Date of event which requires filing of this statement, reflecting beneficial ownership. |
| 2025-08-05 | Date of joint filing agreement and signature date for FMR LLC and Abigail P. Johnson. |
Recommendation
holdThe filing indicates a substantial 15.0% beneficial ownership by FMR LLC, a prominent institutional investor. While this signals strong confidence in Apogee Therapeutics Inc. and is generally a positive indicator, the Schedule 13G itself does not provide financial performance data, operational updates, or strategic guidance necessary for a definitive 'buy' or 'sell' recommendation. Investors should 'hold' their position and await further financial disclosures to make a more informed decision, while recognizing the positive signal from this significant institutional stake.
Keywords
Apogee Therapeutics, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.